The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives
- PMID: 19383846
- PMCID: PMC2888777
- DOI: 10.1158/1535-7163.MCT-08-0706
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives
Abstract
Because camptothecins are effective against previously resistant tumors and are the only class of topoisomerase I (Top1) inhibitors approved for cancer treatment, we developed the indenoisoquinolines. Like camptothecins, the indenoisoquinolines selectively trap Top1-DNA cleavage complexes and have been cocrystallized with the Top1-DNA cleavage complexes. Indenoisoquinolines show antitumor activity in animal models. They have several advantages over the camptothecins: (a) They are synthetic and chemically stable. (b) The Top1 cleavage sites trapped by the indenoisoquinolines have different genomic locations, implying differential targeting of cancer cell genomes. (c) The Top1 cleavage complexes trapped by indenoisoquinolines are more stable, indicative of prolonged drug action. (d) They are seldom or not used as substrates for the multidrug resistance efflux pumps (ABCG2 and MDR-1). Among the >400 indenoisoquinolines synthesized and evaluated, three have been retained as leads for clinical development by the National Cancer Institute: NSC 706744, NSC 725776 (Indimitecan), and NSC 724998 (Indotecan). The trapping of Top1 cleavage complexes by indenoisoquinolines in cells results in the rapid and sustained phosphorylation of histone H2AX (γ-H2AX). We discuss the use of γ-H2AX as a pharmacodynamic biomarker for the clinical development of the indenoisoquinolines.
Figures



Similar articles
-
NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.Clin Cancer Res. 2018 Dec 1;24(23):5830-5840. doi: 10.1158/1078-0432.CCR-18-1498. Epub 2018 Jul 30. Clin Cancer Res. 2018. PMID: 30061364 Free PMC article.
-
Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.Cancer Res. 2007 Nov 1;67(21):10397-405. doi: 10.1158/0008-5472.CAN-07-0938. Cancer Res. 2007. PMID: 17974983
-
Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.J Med Chem. 2003 Jul 17;46(15):3275-82. doi: 10.1021/jm0300476. J Med Chem. 2003. PMID: 12852757
-
Targeting Topoisomerase I in the Era of Precision Medicine.Clin Cancer Res. 2019 Nov 15;25(22):6581-6589. doi: 10.1158/1078-0432.CCR-19-1089. Epub 2019 Jun 21. Clin Cancer Res. 2019. PMID: 31227499 Free PMC article. Review.
-
Topoisomerase 1B poisons: Over a half-century of drug leads, clinical candidates, and serendipitous discoveries.Med Res Rev. 2019 Jul;39(4):1294-1337. doi: 10.1002/med.21546. Epub 2018 Nov 19. Med Res Rev. 2019. PMID: 30456874 Review.
Cited by
-
Chronic exposure to the gibberellin derivative GA-13315 sensitizes breast cancer MCF-7 cells but not colon cancer HCT116 cells to irinotecan.Oncol Lett. 2020 Dec;20(6):281. doi: 10.3892/ol.2020.12144. Epub 2020 Sep 23. Oncol Lett. 2020. PMID: 33014159 Free PMC article.
-
Discovery of 2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-1-one derivatives as possible antileishmanial agents.RSC Med Chem. 2022 May 11;13(6):746-760. doi: 10.1039/d2md00078d. eCollection 2022 Jun 22. RSC Med Chem. 2022. PMID: 35814931 Free PMC article.
-
Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.Clin Cancer Res. 2010 Nov 15;16(22):5447-57. doi: 10.1158/1078-0432.CCR-09-3076. Epub 2010 Oct 5. Clin Cancer Res. 2010. PMID: 20924131 Free PMC article.
-
The dynamic interplay between DNA topoisomerases and DNA topology.Biophys Rev. 2016 Nov;8(Suppl 1):101-111. doi: 10.1007/s12551-016-0240-8. Epub 2016 Nov 14. Biophys Rev. 2016. PMID: 28510219 Free PMC article. Review.
-
NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.Clin Cancer Res. 2018 Dec 1;24(23):5830-5840. doi: 10.1158/1078-0432.CCR-18-1498. Epub 2018 Jul 30. Clin Cancer Res. 2018. PMID: 30061364 Free PMC article.
References
-
- Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6:789–802. - PubMed
-
- Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988;48:1722–1726. - PubMed
-
- Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science. 1989;246:1046–1048. - PubMed
-
- Erickson-Miller CL, May RD, Tomaszewski J, et al. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother Pharmacol. 1997;39:467–472. - PubMed
-
- Cushman M, Cheng L. Stereoselective oxidation by thionyl chloride leading to the indeno[1,2-c]isoquinoline system. J Org Chem. 1978;43:3781–3783.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials